Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST
Processa Pharmaceuticals (NASDAQ: PCSA) will host a conference call on May 13, 2021, at 5:30 PM EST to discuss its Q1 2021 results and provide updates on its clinical pipeline. The call can be accessed via a toll-free number or an international line. The company focuses on developing products to improve survival and quality of life for patients with unmet medical needs, with active pipeline programs for conditions like metastatic colorectal cancer, breast cancer, and GI motility disorders.
- Plans to provide Q1 2021 results and clinical pipeline updates during the call.
- Focuses on unmet medical needs with a strong pipeline including PCS6422, PCS499, and PCS12852.
- None.
HANOVER, MD., May 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announces it will host a conference call and live webcast on May 13, 2021, at 5:30 p.m. EST to discuss its first quarter 2021 results and provide an update on the Company’s clinical pipeline.
Conference Call Information
To participate in this event, please dial in approximately 5 to 10 minutes before the beginning of the call.
Date: May 13, 2021
Time: 5:30 p.m. ET
Toll Free: 888-506-0062; Entry Code: 396394
International: 973-528-0016; Entry Code: 396394
Live Webcast: https://www.webcaster4.com/Webcast/Page/2572/41274
Conference Call Replay Information
Toll-free: 877-481-4010
International: 919-882-2331
Replay Passcode: 41274
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com .
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:
Michael Floyd
mfloyd@processapharma.com
301-651-4256
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com
FAQ
What is the date of the upcoming Processa Pharmaceuticals conference call?
What time is Processa Pharmaceuticals' Q1 2021 results call?
How can I access the conference call for Processa Pharmaceuticals?
What are the main programs in Processa Pharmaceuticals' clinical pipeline?
What is the purpose of the conference call on May 13, 2021?
